Zealand Pharma (ZEAL) Stock Drops 23% on Survodutide Data Concerns

Zealand Pharma (ZEAL) shares fell 23% after revealing that its weight loss drug, survodutide, had a patient dropout rate of 19%, leading analysts to cut peak sales forecasts by nearly 80%. The stock has declined 38% year-to-date and experienced its worst trading days on record since going public in 2010. UBS analysts reduced their price target from 730 to 540 Danish kroner while maintaining a Buy recommendation, focusing on the next potential driver, petrelintide. Although the company faces competition, analysts see promise in amylin drugs like petrelintide that meet the demand for high tolerability.

Informational only, not financial advice. Content is AI-generated and may contain errors. How this works.